You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Market Movers

Acquisition rumors drive up Ariad shares

Ariad can sell Iclusig again, but only to a small segment of patients whose treatment options are limited.

Boston Globe/File 2011

Ariad can sell Iclusig again, but only to a small segment of patients whose treatment options are limited.

Continue reading below

Ariad Pharmaceuticals Inc. stock soared on speculation that the Cambridge biotech is a takeover target. On Thursday and Friday, traders reacted to a report by the Mail, a British news website, that Eli Lilly and Co., GlaxoSmithKline PLC, and Shire PLC made overtures about acquiring Ariad. None of the drug makers would comment. Ariad resumed US sales of its leukemia drug Iclusig last week after suspending sales in October when the FDA issued a safety alert.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week